A Study of the Effects of LY3372689 on the Brain in Healthy Participants

Lilly

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: LY3372689

Diagnostic Test: [18F]LSN3316612

Study type

Interventional

Funder types

Industry

Identifiers

NCT03944031

I9X-MC-MTAB (Other Identifier)

17220

Details and patient eligibility

About

This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to approximately 25 days after enrollment. Screening must be completed within 28 days prior to enrollment.

Enrollment

17 patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Overtly healthy males or females who cannot get pregnant
Have a body mass index (BMI) of at least 18.5 kilogram per square meter (kg/m²), inclusive, at screening
Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
Have veins and arteries suitable for protocol required blood sampling

Exclusion criteria

Have a history of head injury or contraindications to undergoing magnetic resonance imaging (MRI) examination
Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
Have previously participated or withdrawn from this study
Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking for study procedure
Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate or could interfere with understanding the results of the study
Have long exposure to sunlight routinely or use tanning beds regularly
Participate in regular vigorous exercise